Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023.

IF 33.7 1区医学 Q1 Medicine

Mmwr Recommendations and Reports Pub Date : 2023-03-10 DOI:10.15585/mmwr.rr7201a1

Erin E Conners, Lakshmi Panagiotakopoulos, Megan G Hofmeister, Philip R Spradling, Liesl M Hagan, Aaron M Harris, Jessica S Rogers-Brown, Carolyn Wester, Noele P Nelson

{"title":"Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023.","authors":"Erin E Conners, Lakshmi Panagiotakopoulos, Megan G Hofmeister, Philip R Spradling, Liesl M Hagan, Aaron M Harris, Jessica S Rogers-Brown, Carolyn Wester, Noele P Nelson","doi":"10.15585/mmwr.rr7201a1","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic hepatitis B virus (HBV) infection can lead to substantial morbidity and mortality. Although treatment is not considered curative, antiviral treatment, monitoring, and liver cancer surveillance can reduce morbidity and mortality. Effective vaccines to prevent hepatitis B are available. This report updates and expands CDC's previously published Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection (MMWR Recomm Rep 2008;57[No. RR-8]) regarding screening for HBV infection in the United States. New recommendations include hepatitis B screening using three laboratory tests at least once during a lifetime for adults aged ≥18 years. The report also expands risk-based testing recommendations to include the following populations, activities, exposures, or conditions associated with increased risk for HBV infection: persons incarcerated or formerly incarcerated in a jail, prison, or other detention setting; persons with a history of sexually transmitted infections or multiple sex partners; and persons with a history of hepatitis C virus infection. In addition, to provide increased access to testing, anyone who requests HBV testing should receive it, regardless of disclosure of risk, because many persons might be reluctant to disclose stigmatizing risks.</p>","PeriodicalId":51328,"journal":{"name":"Mmwr Recommendations and Reports","volume":null,"pages":null},"PeriodicalIF":33.7000,"publicationDate":"2023-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997714/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mmwr Recommendations and Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15585/mmwr.rr7201a1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Chronic hepatitis B virus (HBV) infection can lead to substantial morbidity and mortality. Although treatment is not considered curative, antiviral treatment, monitoring, and liver cancer surveillance can reduce morbidity and mortality. Effective vaccines to prevent hepatitis B are available. This report updates and expands CDC's previously published Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection (MMWR Recomm Rep 2008;57[No. RR-8]) regarding screening for HBV infection in the United States. New recommendations include hepatitis B screening using three laboratory tests at least once during a lifetime for adults aged ≥18 years. The report also expands risk-based testing recommendations to include the following populations, activities, exposures, or conditions associated with increased risk for HBV infection: persons incarcerated or formerly incarcerated in a jail, prison, or other detention setting; persons with a history of sexually transmitted infections or multiple sex partners; and persons with a history of hepatitis C virus infection. In addition, to provide increased access to testing, anyone who requests HBV testing should receive it, regardless of disclosure of risk, because many persons might be reluctant to disclose stigmatizing risks.

Abstract Image

查看原文本刊更多论文

乙型肝炎病毒感染的筛查和检测：疾病预防控制中心建议 - 美国，2023 年。

慢性乙型肝炎病毒（HBV）感染可导致严重的发病率和死亡率。虽然治疗不能被认为是治愈性的，但抗病毒治疗、监测和肝癌监控可以降低发病率和死亡率。目前已有预防乙型肝炎的有效疫苗。本报告更新并扩展了美国疾病预防控制中心之前发布的《慢性乙型肝炎病毒感染者的识别和公共卫生管理建议》（MMWR Recomm Rep 2008;57[No.RR-8]）中有关美国乙型肝炎病毒感染筛查的内容。新建议包括对年龄≥18 岁的成年人一生中至少进行一次使用三种实验室检测方法的乙型肝炎筛查。报告还扩展了基于风险的检测建议，将以下与 HBV 感染风险增加相关的人群、活动、接触或条件包括在内：在监狱、牢房或其他拘留场所被监禁或曾被监禁的人；有性传播感染史或多个性伴侣的人；以及有丙型肝炎病毒感染史的人。此外，为了提供更多的检测机会，任何要求进行 HBV 检测的人都应接受检测，无论其是否披露风险，因为许多人可能不愿意披露耻辱性风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Mmwr Recommendations and Reports PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

36.00

自引率

0.00%

发文量

期刊介绍： The MMWR series of publications is published by the Office of Science, Centers for Disease Control and Prevention (CDC), U.S. The MMWR Recommendations and Reports contain in-depth articles that relay policy statements for prevention and treatment in all areas in the CDC’s scope of responsibility (e.g., recommendations from the Advisory Committee on Immunization Practices).